The issue of what constitutes a pharmaceutical substance is a recurrent theme in Australian law, and is once again up for discussion. Paul Whenman of FB Rice & Co looks into the debate... »
Pharmaceuticals & Medicals


Guest bloggers Donal O'Connell and Sabine Baum offer tips on how to control a network of IP agents as your company grows and adapts... »


Economic instability will leave indelible marks on legal business, according to Fulbright & Jaworski’s new analysis of UK and US litigation habits... »




There is no question that the worst recession for 80 years has had a major impact on the legal sector, writes Bryan Hughes. But what will be the long-term effect on law firms? Eversheds LLP’s ‘Law.... »


Often dubbed ‘patent trolls’, non-practising entities are far from ugly in the eyes of investors. Netting an estimated $6-$8bn of investment in the past eight years, they are a major force in IP m.... »


A vast region with a rich linguistic heritage, Asia can be a minefield for ill-prepared trademark applications. Matt Packer looks at the potential stumbling blocks and outlines some practical solution.... »


Office for National Statistics research proves that the UK economy should be realigned around intellectual property, says specialist law firm Mathys & Squire... »


As junior lawyers find it harder to take on corporate client work, Matt Packer’s new blog explains how the legal services outsourcing sector could help them build their skills... »


While they are harmonious on cultural matters, Australia and New Zealand have their differences on issues of patentability, says Brett Lunn of FB Rice & Co... »




